Seeking Alpha
Seeking Alpha Portfolio App for iPad
Finance
(1)
Market Currents

Questcor Pharmaceuticals (QCOR -6.3%) says the number of paid prescriptions for its primary...

  • Friday, March 9, 2012, 11:59 AM ET
    Questcor Pharmaceuticals (QCOR -6.3%) says the number of paid prescriptions for its primary product, Acthar, dipped M/M in February. The result contrasts with the general pattern of explosive growth for Acthar, as QCOR has quickly built up its salesforce to promote the drug used to treat multiple sclerosis and other diseases.
Track new comments on this story

This news story has 3 comments:

  •  
    Insiders sold by the droves in 2011. Maybe they're not the only ones who saw the top of $45.95 at a PE of 56 as too high. Short interest increased. Momentum traders evacuated. Short interest & profit takers prevail. Growth stymied. What would you expect other than a falling stock? -Ernest
    11 Mar 2012, 12:54 PM Reply Like
  •  
    Insiders should give the stock another look. Acthar gel is the ONLY drug that works to relieve epilepsy in infants. QCOR can charge whatever they want and they DO!! Profits are up and up and the fact they filled 4 less prescriptions this month does not change the fact they are going to come out making 150% EPS gains quarter after quarter.
    13 Mar 2012, 11:30 AM Reply Like
  •  
    Oy! I sure hope you don't mean 150% Q after Q Sequentially. lol -Ernest
    14 Mar 2012, 10:07 AM Reply Like
LATEST|
TODAY SO FAR|
YESTERDAY
Other date
DJIA (DIA) S&P 500 (SPY)

HEALTHCARE ETFs IN FOCUS

Latest Healthcare Articles
More Latest Articles »